BeyondSpring Pharmaceuticals to Present at 18th Annual BIO CEO & Investor ...
BeyondSpring's lead therapeutic candidate, Plinabulin, has begun a Phase III study to treat non-small-cell lung carcinoma (“NSCLC”). This 550-patient clinical trial is being conducted in the United States, China, and Australia. Evaluation and ...
GlobeNewswire (press release) - Wed, 03 Feb 2016 05:30

Lung Cancer Presents Differently in Younger Patients
Histologically, the investigators found adenocarcinoma to be the most common cancer type, presenting in 65% of the patients. This was followed by squamous cell carcinoma, in 10% of the patients; undifferentiated non-small cell carcinoma, occurring in 8 ...
Clinical Oncology News - Tue, 02 Feb 2016 10:42



Identification of microRNA expression profile related to lymph node status in ...
In the same way, miR-184 functions as a tumor suppressor in various cancers (renal carcinoma, glioma, non-small-cell lung cancer, oral squamous cell carcinoma, breast cancer) by repressing oncogenes such as TNFAIP2, SND1, CDC25A, c-MYC,39 and ...
Nature.com - Fri, 05 Feb 2016 04:33



Where Does Immuno-Oncology Fit in a Value-Based Care Delivery Model?
Two checkpoint blockade drugs gained FDA approval for non–small cell lung cancer (NSCLC). The first was based on a study showing that patients previously treated with chemotherapy who received nivolumab had a 1-year OS of 42% compared with a 24% ...
AJMC.com Managed Markets Network - Fri, 05 Feb 2016 07:33

FDA expands Opdivo use for metastatic melanoma
Earlier this year, FDA approved Opdivo to treat patients with advanced squamous non-small cell lung cancer (NSCLC) and then, in early October, FDA expanded the use of Opdivo to also treat patients with non-squamous NSCLC. In late November, FDA also ...
ModernMedicine - Tue, 02 Feb 2016 08:52

Reviewing Results from COMPARZ and PISCES Clinical Trials
Carlos H. Barrios, MD: Well, after the revolution we had in the treatment of renal cell cancer in the decade of the 2000s, we lacked direct evidence of comparisons amongst these different agents that were brought into clinical practice. ... So pointing ...
OncLive - Fri, 05 Feb 2016 13:33



Engineering therapeutic antibodies targeting G-protein–coupled receptors
GPCRs targeting neuropeptides, including gastrin-releasing peptide, endothelin, bradykinin, neuromedin B, cholecystokinin and angiotensin II are activated in many types of cancers such as small-cell lung cancer, pancreatic cancer, prostate cancer and ...
Nature.com - Fri, 05 Feb 2016 00:00



Combining Nivolumab With Radiation Shows Promise in Melanoma Patients With ...
Researchers of Moffitt Cancer Center analyzed data from 26 patients with 73 brain metastases from two separate prospective clinical trials at the center. Radiation was administered prior to, during, and after nivolumab in 33 lesions (45%), 5 lesions (7 ...
OncLive - Tue, 02 Feb 2016 08:29


<-   1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014